Health booking company HealthEngine has urged the court to accept a $2.9 million penalty for deleting and altering unfavourable reviews, telling a judge that it did not know the behaviour was against the law.
After “unavoidable delays”, shareholders will soon be notified of a settlement reached one year ago in a class action against QRxPharma, but a company director has warned group members will receive nothing of consequence and the law firm and funder involved in the case would be disappointed by their takeaways.
AFT Pharmaceuticals has suffered another blow over its Maxigesic advertisements, with a judge finding the marketing material misled consumers by claiming to provide better, faster and more effective pain relief than paracetamol or ibuprofen.
Generic drug maker Sandoz has successfully appealed a $26.3 million judgment finding it infringed a patent owned by rival H Lundbeck relating to the top-selling antidepressant Lexapro.
Veterinary pharmaceutical company Norbrook Laboratories has filed court proceedings after a delegate of IP Australia tossed its opposition to a patent by Bayer New Zealand for a bovine antiseptic treatment.
Brisbane clothing company Lorna Jane has been fined almost $40,000 for implying that its ‘anti-virus activewear’ prevents against infectious diseases such as COVID-19.
A judge has ordered private health insurer Medibank to pay $5 million in penalties for rejecting the claims of hundreds of members who were entitled to coverage for critical medical procedures, including spinal surgery.
Global animal health company Zoetis has told the lead applicants in a class action over horse vaccines to “put up or shut up” and produce evidence disclosing an alleged scientific link between the hendra virus vaccine and certain alleged adverse side effects.
The lead applicants in a class action against The Cosmetic Institute have added 11 cosmetic surgeons to the lawsuit, alleging they conducted breast augmentation surgery in an “incompetent” manner.
Mylan Health has lost its challenge to a ruling that invalidated three patents related to its blockbuster cholesterol drug Lipidil, despite the appeals court finding the primary judge had erred by ruling that proof of intention was required for Swiss-style claims.